IQVIA (NYSE:IQV - Get Free Report) had its price target increased by equities researchers at Mizuho from $190.00 to $225.00 in a report issued on Friday, July 25th, Marketbeat.com reports. The firm currently has an "outperform" rating on the medical research company's stock. Mizuho's target price suggests a potential upside of 23.33% from the company's previous close.
Several other research firms have also weighed in on IQV. Citigroup restated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Evercore ISI boosted their price objective on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Barclays boosted their price objective on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Redburn Partners set a $188.00 price objective on IQVIA in a research note on Friday, May 23rd. Seven analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.
View Our Latest Stock Analysis on IQV
IQVIA Trading Down 1.8%
Shares of IQV stock traded down $3.42 during trading hours on Friday, hitting $182.44. 1,644,130 shares of the company were exchanged, compared to its average volume of 2,321,248. The firm has a market cap of $31.01 billion, a P/E ratio of 26.40, a P/E/G ratio of 2.04 and a beta of 1.30. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a 50 day simple moving average of $162.11 and a two-hundred day simple moving average of $170.07.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the firm posted $2.64 EPS. IQVIA's revenue was up 5.3% compared to the same quarter last year. Equities analysts anticipate that IQVIA will post 10.84 EPS for the current year.
Insiders Place Their Bets
In related news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.
Hedge Funds Weigh In On IQVIA
Hedge funds have recently bought and sold shares of the business. Everpar Advisors LLC lifted its position in shares of IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock valued at $221,000 after acquiring an additional 62 shares in the last quarter. Continuum Advisory LLC increased its stake in IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares during the last quarter. Private Trust Co. NA increased its stake in IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company's stock worth $95,000 after acquiring an additional 67 shares during the last quarter. Ballentine Partners LLC grew its stake in shares of IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after buying an additional 69 shares in the last quarter. Finally, Independent Advisor Alliance grew its stake in shares of IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after buying an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.
IQVIA Company Profile
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories

Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.